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Abstract
Background: CXCL12 is a chemokine that is constitutively expressed in many organs and tissues. CXCL12 promoter
hypermethylation has been detected in primary breast tumours and contributes to their metastatic potential. It has
been shown that the oestrogen receptor a (ESR1) gene can also be silenced by DNA methylation. In this study, we
used methylation-specific PCR (MSP) to analyse the methylation status in two regions of the CXCL12 promoter and
ESR1 in tumour cell lines and in primary breast tumour samples, and correlated our results with clinicopathological
data.
Methods: First, we analysed CXCL12 expression in breast tumour cell lines by RT-PCR. We also used 5-aza-2’-
deoxycytidine (5-aza-CdR) treatment and DNA bisulphite sequencing to study the promoter methylation for a
specific region of CXCL12 in breast tumour cell lines. We evaluated CXCL12 and ESR1 methylation in primary
tumour samples by methylation-specific PCR (MSP). Finally, promoter hypermethylation of these genes was
analysed using Fisher’s exact test and correlated with clinicopathological data using the Chi square test, Kaplan-
Meier survival analysis and Cox regression analysis.
Results: CXCL12 promoter hypermethylation in the first region (island 2) and second region (island 4) was
correlated with lack of expression of the gene in tumour cell lines. In the primary tumours, island 2 was
hypermethylated in 14.5% of the samples and island 4 was hypermethylated in 54% of the samples. The ESR1
promoter was hypermethylated in 41% of breast tumour samples. In addition, the levels of ERa protein expression
diminished with increased frequency of ESR1 methylation (p < 0.0001). This study also demonstrated that CXCL12
island 4 and ESR1 methylation occur simultaneously at a high frequency (p = 0.0220).
Conclusions: This is the first study showing a simultaneous involvement of epigenetic regulation for both CXCL12
and ESR1 genes in Brazilian women. The methylation status of both genes was significantly correlated with
histologically advanced disease, the presence of metastases and death. Therefore, the methylation pattern of these
genes could be used as a molecular marker for the prediction of breast cancer outcome.
Background
Breast cancer development and progression is influenced
by intrinsic properties of the tumour cells, as well as by
macro-environmental factors. There is an extensive inter-
play between tumour cells and signalling molecules such
as chemokines [1,2]. Chemokine receptors and growth
factors have been extensively implicated in the metastatic
process of breast cancer [3]. A chemokine-mediated
process of tumour cell homing to specific metastatic sites
requires an enrichment in the site of metastasis forma-
tion for specific chemokines; these chemokines are then
able to induce the migration of tumour cells that express
the corresponding receptors [3]. CXCL12, formerly
known as stromal cell-derived factor-1 (SDF-1a), is a
CXC subfamily of chemokines that is expressed by stro-
mal cells, including fibroblasts and endothelial cells.
CXCL12 is also known to be present in the organs that
are target for metastasis in breast cancer [1]. * Correspondence: giseli@ufpr.br
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due to a combination of genetic and epigenetic events.
Aberrant gene silencing in mammalian cells is asso-
ciated with promoter methylation, and it is known that
many regions of the genome are methylated at one or
more CpG sites [4,5]. Recent studies have also demon-
s t r a t e dt h a tt h eCXCL12 gene modulates metastatic
potential in breast and colon carcinomas, where it con-
trols its own regulation in an autocrine loop. Epigenetic
silencing causes the loss of autocrine expression and
results in an imbalance in the expression levels of
CXCL12 and its receptor, CXCR4 [6,7].
Sixty percent of primary breast tumours are ERa-posi-
tive, and two-thirds of advanced breast tumours respond
to therapy with anti-estrogens such as tamoxifen (Noval-
dex®) [8]. However, a fraction of tumours that are ERa-
positive at diagnosis subsequently lose ERa expression
during the progression of the disease [9]. Hypermethyla-
tion of the oestrogen receptor a gene (ESR1)i sac o m -
mon occurrence in several specific populations and for
workers in a number of occupations; it seems to be a
relevant factor for hormonal treatment [10,11]. In this
study, we evaluated the methylation patterns of ESR1 and
two CpG islands in the CXCL12 gene in breast tumour
samples from Brazilian women. This is the first study to
report an association between simultaneous DNA methy-
lation of these two genes compared to other prognostic
factors in breast cancer among Brazilian women.
Methods
Cell Lines
Breast tumour cell lines were all obtained from the Lud-
wig Institute for Cancer Research, (São Paulo, Brazil).
The following cell lines were used: MDA-MB-436,
MDA-MB-435, MDA-MB-231, MCF-7, PMC42, HB4a
(control immortalized normal cells) [12] and HB4aC3.6
[13]. The cell lines were cultured in RPMI 1640 medium
[14] containing 10% foetal bovine serum (supplemented
with 0.2 mM glutamine, and 40 μg/mL garamycin, 10
μg/mL insulin, if necessary) at 37°C in a humidified
incubator with 5% CO2.
Patient samples
Frozen samples of breast tumours (n = 69) used for
methylation analysis were obtained from patients treated
by primary surgery for breast cancer at the Nossa Sen-
hora das Graças Hospital, Curitiba, PR, Brazil with insti-
tutional approval (Process number 25000.007020/2003-
93; CONEP register 7220 opinion number 251/2003).
The study included only female patients with invasive
breast tumours. All patients gave informed consent for
the study to retain and analyse their tissue for research
purposes. The ages of the patients ranged from 27 to 84
years (mean 57.8 ± 14.7). Histological types were either
infiltrative ductal carcinoma (IDC) (n = 51, 73.9%) or
infiltrative lobular carcinoma (ILC) (n = 18, 26.1%). The
lymph node status of the patients was positive (n = 35,
51.5%) or negative (n = 33, 48.5%). Histologic grade was
determined according to the modified Bloom-Richard-
son criteria. Of the patients, 27.6% were Grade I, 47.8%
were Grade II and 24.6% were Grade III. TNM staging
was done according to official classification methods
[15]. Other clinicopathological data (tumour size, local
recurrence, metastasis and death) are summarised in
Table 1.
Immunohistochemistry
Standard immunohistochemical (IHC) detection was
performed on sections from archival paraffin embedded
breast tumour tissues. Protein expression in malignant
breast tissues was detected with specific antibodies
against estrogen receptor (ER) and progesterone recep-
tor (PR); clones 1D5 and PgR 636 (DAKO), respectively.
Monoclonal mouse anti-human antibodies were pre-
diluted and incubated for 18 h at 4°C according to the
manufacturer’s instructions. The rabbit polyclonal anti-
body against HER2 detection was performed by the Her-
cepTest™ (DAKO CYTOMATION code K5204). In
addition, positive and negative controls for each marker
were routinely performed during experiments.
Sections were then processed using the EnVision™-
FLEX Target Retrieval Solution (DAKO) according to
the manufacture’s recommendations. Immunohisto-
chemical staining of the samples was evaluated and
scored by two pathologists who were responsible for
clinicopathological data. The cutt-of value for ER and
PR status values was 10% of cells. Fifty-seven ERa-posi-
tive tumours were scored based on the number of posi-
tive cells present in IHC staining. The slides were
scored following the criteria: <10% tumour cells showing
nuclear staining scored as 0, 10-30% tumour cells show-
ing nuclear staining scored as 1, 30-50% tumour cells
showing nuclear staining scored as 2, >50% tumour cells
showing nuclear staining scored as 3.
RNA extraction and reverse transcription
Total RNA was isolated using the TRIzol Reagent (Life
Technologies, USA) according to the protocol supplied by
the manufacturer. Reverse transcription reactions were per-
formed using 500 ng of DNA-free RNA, an oligo (dT)12-18
primer and Superscript II Reverse Transcriptase (Gibco,
BRL). PCR was performed using CXCL12-specific primers,
and GAPDH was used as a housekeeping control (Table 2).
The PCR was performed in a volume of 20 μlc o n t a i n i n g
1× PCR buffer (Invitrogen), 1.5 mM MgCl2 (Invitrogen),
200 μMd N T P s ,0 . 3μM of each primer and 1 U of Taq Pla-
tinum (Invitrogen). The PCR conditions were as follows: 95°
C for 10 min, 94°C for 45 s, the appropriate annealing
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of 72°C for 5 min. PCR products were resolved on 1% agar-
ose gels and visualised by ethidium bromide staining.
5-aza-2’-deoxycytidine (5-aza-CdR) treatment
The cell lines MDA-MB-231, MDA-MB-435 and MDA-
MB-436 were analysed using this technique. Cells were
plated (10
6 cells/ml) and treated for 7 days with 1 μM
5-aza-CdR (Sigma Aldrich, Deisenhein, Germany) or left
untreated. The medium was changed every day, and no
significant cell death was observed. After 7 days of treat-
ment, total RNA was isolated. The expression of
CXCL12 in breast tumour cells was analysed by RT-
PCR using the housekeeping gene GAPDH as an inter-
nal control. PCR products were resolved on 1% agarose
gels and visualised by ethidium bromide staining.
Table 1 Clinicopathological features of the 69 patients with primary breast carcinomas according to methylation
status of CXCL12 and ESR1 genes
Variables Samples (%) CXCL12 methylation
(a) p
a CXCL12 methylation
(b) p
b ESR1 methylation
(c) p
c
M (%) U (%) M (%) U (%) M (%) U (%)
Age
< 45 9 (13) 0 9 (100) 0.3378 3 (33) 6 (67) 0.2853 2 (22) 7 (78) 0.2937
≥ 45 60 (87) 10 (17) 50 (83) 34 (56.7) 26 (43.3) 26 (43) 34 (57)
Stage
I 13 (19.7) 2 (15.4) 11 (84.6) 5 (38.5) 8 (61.5) 1 (7.7) 12 (92.3)
II 31 (47) 5 (16.1) 26 (83.9) 0.9691 13 (42) 18 (58) 0.3696 10 (32.3) 21 (67.7) 0.0003
III/IV 22 (33.3) 3 (14) 19 (86) 13 (59.1) 9 (40.9) 16 (72.7) 6 (27.3)
Tumour size
pT1 19 (27.6) 4 (21) 15 (79) 10 (53) 9 (47) 4 (21) 15 (79)
pT2 36 (52.2) 4 (11.1) 32 (88.9) 0.6088 17 (47.2) 19 (52.8) 0.3034 13 (36.1) 23 (63.9) 0.0029
pT3/pT4 14 (20.2) 2 (14.3) 12 (85.7) 10 (71.4) 4 (28.6) 11 (78.6) 3 (21.4)
SBR
I 19 (27.6) 4 (21.1) 15 (78.9) 7 (36.8) 12 (63.2) 2 (11) 17 (89)
II 33 (47.8) 4 (12) 29 (88) 0.4178 17 (39.4) 16 (60.6) 0.0180 14 (42.4) 17 (57.6) 0.0011
III 17 (24.6) 2 (11.8) 15 (88.2) 13 (65) 4 (35) 12 (71) 5 (29)
Lymph node status
Positive 35 (51.5) 5 (14.3) 30 (85.7) 1.0000 22 (63) 13 (37) 0.2231 19 (54.3) 16 (45.7) 0.0288
Negative 33 (48.5) 5 (15.1) 28 (84.9) 15 (45.4) 18 (54.6) 9 (27.3) 24 (72.7)
Estrogen receptor
Positive 57 (83.8) 7 (12.2) 50 (87.8) 0.6312 29 (51) 28 (49) 0.2084 19 (33) 38 (67) 0.0054
Negative 11 (16.2) 2 (18.2) 9 (81.8) 8 (73) 3 (27) 9 (81.8) 2 (18.2)
HER2
Positive 20 (31.3) 5 (25) 15 (75) 0.0955 12 (60) 8 (40) 0.5996 10 (50) 10 (50) 0.4249
Negative 44 (68.7) 3 (6.9) 41 (93.1) 23 (52.3) 21 (47.7) 17 (38.6) 27 (61.4)
Progesterone receptor
Positive 45 (65) 7 (17) 38 (83) 1.0000 25 (56) 20 (44) 1.0000 16 (36) 29 (64) 0.0808
Negative 16 (35) 2 (12.5) 14 (87.5) 9 (56.3) 7 (43.7) 10 (62.5) 6 (37.5)
Metastasis
Positive 15 (22.4) 3 (20) 12 (80) 0.4075 14 (93) 1 (7) 0.0008 13 (86.7) 2 (13.3) < 0.0001
Negative 52 (77.6) 6 (11.5) 46 (88.5) 23 (44) 29 (56) 14 (26.9) 38 (73.1)
Recurrence
Positive 8 (12) 2 (25) 6 (75) 0.3413 6 (75) 2 (25) 0.2700 4 (50) 4 (50) 0.7049
Negative 59 (88) 8 (13.5) 51 (86.5) 30 (51) 29 (49) 23 (39) 36 (61)
Death
Positive 17 (26) 4 (23.5) 13 (76.5) 0.2250 15 (88) 2 (12) 0.0019 13 (76.5) 4 (23.5) 0.0013
Negative 48 (74) 5 (10.4) 43 (89.6) 21 (43.7) 27 (56.3) 14 (37.8) 33 (62.2)
Histological type
IDC 51 (73.9) 8 (15.7) 43 (84.3) 1.0000 30 (58.8) 21 (41.2) 0.1759 20 (39.2) 31 (60.8) 0.7829
ILC 18 (26.1) 2 (11.1) 16 (88.9) 7 (39) 11 (61) 8 (44.4) 10 (55.6)
Abbreviations: a, data of CXCL12 CpG island-2; b, data of CXCL12 CpG island-4; c, data of ESR1 gene; p, value from statistical analysis c
2 test and Fisher’s exact
test; M, methylation results; U, unmethylation results; significant data are in bold.
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Genomic DNA was prepared from breast cancer cell
lines or frozen tumour samples by the phenol/chloro-
form protocol [16]. They were then subjected to sodium
bisulphite treatment using the EpiTect® Bisulphite Kit
(Qiagen) according to the manufacturer’s instructions.
CXCL12 CpG island methylation analysis
Previous studies used the MSP technique to evaluate the
regulation of CXCL12 expression by DNA methylation
and in this study we have utilized the designed primers
for this region (island 2), as described [7].
In an attempt to determine all CpG islands and all
potential transcription start sites (TSS) for CXCL12,w e
first proceeded with the identification of the promoter
sequence [17]. The analyses were initiated using an
identified RefSeq by GenBank accession number, after
which we submitted the gene sequence to a Genome
BLAT Search through the UCSC Genome bioinfor-
matics website http://genome.ucsc.edu. We selected
2000 bps of sequence extending from the 5’ upstream
region to 1000 bps downstream of the region of the
TSS. The BLAT program returned a sequence of 5677
bps that was first submitted to the CpGPLOT program
from the European Bioinformatics Institute website
http://www.ebi.ac.uk/emboss/cpgplot. This program
defines a CpG island as ≥ 200 bps of sequence with ≥
50% C + G content and ≥ 0.6 CpG observed/CpG
expected. The 5677 bps from CXCL12 that we have ana-
lysed contained five CpG islands in a region of 3447 bps
(Figure 1A). The 5677 bps sequence was also submitted
to computational analysis to predict transcription factor
binding sites using TESS http://www.cbil.upenn.edu/cgi-
bin/tess/tess and MatInspector http://www.genomatix.
de/[18]. The DNA region we refer to as island 4 (Figure
1A) is positioned next to an estrogen responsive ele-
ment (ERE) binding site that could be involved in breast
cancer. This CpG island was also selected for methyla-
tion status analyses in this study.
Island 4 was amplified from bisulphite-treated DNA
samples using a nested-PCR amplification protocol. The
two sets of primers were used for the nested reactions
at their appropriate annealing temperatures, and are
shown in Table 2. The first PCR reactions were per-
formed as described below: 1 cycle of 95°C for 10 min,
94°C for 3 min, the appropriate annealing temperature
for 3 min, 72°C for 2 min; 5 cycles of 94°C for 3 min,
annealing temperature for 3 min, 72°C for 2 min; 35
cycles of 94°C for 1 min, annealing temperature for 1
min, and 72°C for 5 min. Amplified products were puri-
fied using the Qiaquick Gel Extraction Kit (Qiagen) and
cloned into a pCR2.1 cloning vector (Invitrogen). Eight
clones were sequenced for each cell line using the uni-
versal or reverse primers. DNA sequencing reactions
were performed using Big Dye Terminator technology
(Applied Biosystems) on an ABI 377 sequencer (Applied
Biosystems) according to the manufacturer’si n s t r u c -
tions. One hundred percent methylation was obtained if
a methylated cytosine in the CpG dinucleotides was pre-
sent in eight sequenced clones. The methylation percen-
tage for each tumour cell line (global methylation
pattern) was calculated by dividing the number of
methylated CpG dinucleotides by the total number of
CpGs analysed.
Methylation-specific PCR (MSP)
Methylation-specific PCR was performed as previously
described [19] and the CXCL12 primer sequences for
Table 2 Summary of primer sequences, used for RT-PCR, nested-PCR and MSP
Application and specificity CpG status Forward primer (5’-3’) Reverse primer (5’-3’) Product
size (bp)
Annealing
T (°C)
Ref.
RT-PCR
CXCL12 - CAACGTCAAGCATCTCAA AGCTGCAATATCATACCGTA 383 58 This work
GAPDH - CTGCACCACCAACTGCTT A CATGACGGCAGGTCAGGTC 296 63
nested-PCR
CXCL12 - GTAGTGAGGTTTAGTGAAG CCATAAATACCACAATAACTTC 479 51, 53, 55 This work
CXCL12-nested - AGGTTTTTGTTGGGTTGG CAAATCCTAAATCCAACTAC 338 53, 55, 57
SATR-1 - GTTATATTATTTTTTGTTTTTTTG ACATTTCCTTATAATATTATTCC - 48, 50, 52 [21]
SATR-1 nested - TATAGTGGTGGTGTATATTTG CACCTAACCTATAATATTTCTTC 690 52, 54, 56
MSP
CXCL12- (2) U GAGTTTGAGAAGGTTAAAGGTTGG CAAAAAATAAAAATACAACA 249 50 [7]
CXCL12- (2) M GTTAAAGGTCGGAGCGTATTG ACGAAAAATAAAAATACGACGAT 237 59.5
CXCL12- (4) U GTCGTAGCGTTGGGGTT AACGAAACTACGCGCGACT 200 57.8 This work
CXCL12- (4) M GTTGTAGTGTTGGGGTTT AAACAAACAAAACTACA 189 64
ESR1 M ACGAGTTTAACGTCGCGGTC ACCCCCCAAACCGTTAAAAC 140 57.6 [20]
Abbreviations: M, specific for methylated condition; U, specific for unmethylated condition; (2), primers designed for CpG island 2; (4), primers designed for CpG
island 4; ESR1, estrogen receptor gene.
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Page 4 of 13island 2 [7] can be visualized in the Table 2. gDNA
from the primary breast tumours was bisulphite-modi-
fied and amplified with CXCL12 primers specific for
methylated (M) and unmethylated (U) DNA. Analysis of
methylation of the ESR1 promoter was performed using
the set of primers described by Li et al. [20]. PCR reac-
tions were performed with 1 μLo fm o d i f i e dD N A ,1 ×
PCR Buffer (Invitrogen), 1.5 mM (for CXCL12)o r2 . 5
mM (for ESR1)o fM g C l 2 (Invitrogen), 200 μMd N T P s ,
0.3 μMo fe a c hp r i m e ra n d1Uo fT aq Platinum (Invi-
trogen). The PCR protocol was 95°C for 10 min; 38
cycles of 94°C for 45 s, the appropriate annealing tem-
perature for 30 s and 72°C for 45 s, followed by a final
extension of 72°C for 5 min. DNA modification was
confirmed by a nested-PCR reaction with a set of
primers for a previously described satellite region
(Table 2). This reaction was used as a control for bisul-
phite modification quality [2 1 ] .T h i sP C Rr e a c t i o n ,t h e
nested-PCR and temperature conditions are described in
Table 2. The amplification products were separated on
2% agarose gels and stained with ethidium bromide.
Statistical analysis
The statistical analysis was carried out using SPSS pro-
gram (version 16.0, SPSS Inc., Chicago, Illinois, USA).
Associations between specific clinicopathological para-
meters were analyzed using Chi square test and Fisher’s
exact test. Statistical significance was assumed for p <
0.05. The overall survival was calculated from the time
of diagnoses of disease to the occurrence of death. Sur-
vival data were censored on 30
th June, 2009, which was
the date in which the survival data were correlated with
Figure 1 The CpG island of the CXCL12 gene. (A) The CpG island is inside an area from -2594 to +853 (data of the CpGPlot program). The
vertical lines correspond to the CpG dinucleotides. The numbers above correspond to the distance in relation to the +1 (TSS). The area
considered with promoter activity is outlined and it corresponds to the position -1010 to +122 [22]. (B) Twenty-seven dinucleotides are
represented in the figure and positioned in scale. Its localization is signaled below in the figure and the distance in relation to the +1 (TSS). The
ERE factor binding is located 19 nucleotides upstream to the CpG island 4 in nucleotides -1900 to -1918. (C) Twenty-seven dinucleotides are
numbered in agreement with the sequence. The open circles represent the unmethylated dinucleotides while the dark portion represents the
percentage of methylation. On the right side methylation pattern are represented according to data of RT-PCR and the absolute percentage
value. The MSP primers for the condition M (methylated) and U (unmethylated) for this island are located below in the figure. (D) Representative
examples of sequenced tumours. On the right the methylation percentage of three primary tumours is represented. Global % is the number of
methylated CpGs divided by the total analyzed.
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Page 5 of 13the death registry for the last time of a means of 91
months after onset of the disease. Kaplan-Meier esti-
mates are presented for the survival functions, and dif-
ferences in survival were analyzed using the log rank
test. Multivariate analysis was conducted with a back-
ward application of Cox proportional hazards regression
analysis was used to estimate hazards ratio (HR) and
95% confidence intervals (95% CI) for overall survival
and metastasis-free survival. All covariates with p < 0.25
were retained in the final model.
Results
CXCL12 expression in breast tumour cell lines
We first analysed the CXCL12 expression pattern in
seven breast tumour cell lines using RT-PCR. A tran-
script of 383 bps corresponding to the CXCL12 gene was
detected in the less aggressive carcinoma cell lines MCF-
7 and PMC42, in the normal cell line HB4a and in the
modified normal cell line HB4aC3.6 with ERBB2 overex-
pression (Figure 2A). In contrast, no detectable levels of
CXCL12 expression were observed in the highly aggres-
sive tumour cell lines MDA-MB-435, MDA-MB-436 or
MDA-MB-231. To definitively determine if CXCL12
expression was, in fact, lost, all analyses were repeated at
least twice. GAPDH expression was detected in all
samples (Figure 2A). These data are in agreement with
the literature [6], except in the case of the normal cell
lines and the tumour cell lines MDA-MB-436 and
PMC42, where such data have not been previously
described.
CXCL12 silencing by DNA methylation
To confirm the epigenetic transcriptional silencing of
CXCL12, we treated the MDA-MB-435, MDA-MB-436
and MDA-MB-231 breast tumour cell lines with the
demethylating agent 5-aza-2’-deoxycytidine (5-aza-CdR).
The expression of CXCL12 was restored in MDA-MB-
435 cells upon treatment as previously observed [6].
Expression of CXCL12 was also restored in MDA-MB-
231 cells, but not in MDA-MB-436 cells (Figure 2B).
The CpGPlot program analysis of 5677 bps of the 5’
region of the CXCL12 gene identified five putative islands
in the CXCL12 promoter region. The CpG island is posi-
tioned in an area extending from -2594 to +853 (Figure
1A). In this region, five distinct CpG-rich regions were
identified in the positions +512 to +853 (island 1), -840
to +506 (island 2), -1118 to -893 (island 3), -1872 to
-1575 (island 4) and -2594 to -2323 (island 5). The region
comprised of island 2 studied in the breast and colon car-
cinomas [6,7] was -493 to +168 relative to the TSS and
MDA-MB-231
MDA-MB-436
MDA-MB-435
400 bp
300 bp
CXCL12
GAPDH
MM NC HB4a
HB4aC3.6
PMC42
MCF-7 A
B
435 5-AzaCdR 
231 5-AzaCdR
MM NC 435 Mock
231 Mock
436 5-AzaCdR
400 bp
300 bp
CXCL12
GAPDH
436 Mock
Figure 2 CXCL12 expression in breast normal and tumour cell lines and expression after 5-aza-2’-deoxycytidine (5-aza-CdR) treatment.
(A) The bands represent positive results for CXCL12 expression (383 bps) and GAPDH gene was used as housekeeping control (296 bps). (B)
CXCL12 expression evaluation after 5-aza-CdR treatment in MDA-MB-435, MDA-MB-436 and MDA-MB-231 cell lines. The cell lines named Mock
were not treated, and those named 5-aza-CdR were treated showing the re-expression of CXCL12 on these cell lines. H2O was used as negative
control and MM 100 bp was used as a molecular weight marker.
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Page 6 of 13promoter activity was found in the region from -1010 to
+122 [22]. The search for transcription factor binding
sites by computational analysis revealed eight oestrogen
responsive element (ERE) consensus sites, which are
defined as 13 bps perfect palindromic inverted repeats
with a 3 bps spacing of variable bases (n)
5’GGTCAnnnTGACC 3’ [23]. Five of these sites are very
d i s t a n tf r o mt h eT S S ,t w oa r ei n s i d ei s l a n d2a n dt h e
essential GACC sequence is absent. Only one site with
t h es e q u e n c ea G c t g c t g g G A C C( capital letters for those
that match with the consensus), which lies 19 bps away
from island 4, might be an oestrogen-binding site (Figure
1B). Therefore, we complemented our tumour sample
analysis with MSP for CXCL12 CpG island 4.
Sodium bisulphite sequencing was carried out on a
297 bps DNA fragment containing 27 CpG dinucleo-
tides (-1872 to -1575) (Figure 1B). We analysed the
methylation pattern of eight independent alleles (eight
clones) from HB4a and HB4aC3.6 normal cell lines, as
well as the PMC42, MCF-7, MDA-MB-436, MDA-MB-
435, MDA-MB-231 breast tumour cell lines. The methy-
lation pattern varied among the different cell lines as
s h o w ni nF i g u r e1 C .T h eCXCL12-negative cell lines,
MDA-MB-436 (71%) MDA-MB435 (84%) and MDA-
MB-231 (78%) showed CpG dinucleotide hypermethyla-
tion. In contrast, the CXCL12-positive cell lines, HB4a
(11%), HB4aC3.6 (4%), PMC42 (12%) and MCF-7 (5%),
had lower levels of CpG dinucleotide methylation (Fig-
ure 1C). These results were in agreement with our
expression analysis (Figure 2A). On the other hand, the
breast tumour cell line MDA-MB-436 had a dense area
of methylated DNA and did not regain expression of the
CXCL12 gene when cultured with the demethylating
agent 5-aza-CdR (Figure 2B). The importance of DNA
methylation in cancer has been well established [24],
and the focus in the field is now changing to include
the mechanisms by which other chromatin modifica-
tions play a role in cancer development. Among these
changes are the covalent modifications of histones that
can control gene activity. Histone acetylation and
methylation of specific lysine residues, such as lysine 9
in histone H3 or lysine 27 in histone H3, clearly partici-
pate in the silencing of genes [25].
We also evaluated the CpG dinucleotide sequence for
island 4 in the primary breast tumour samples 1, 3 and
8 (Figure 1D). These samples were chosen from the
MSP data analysis, and we have confirmed the pattern
that was described.
MSP analysis in breast tumour cell lines
Dinucleotides 4 and 5, and 21-24, which were chosen
for the design of methylation-specific PCR (MSP) pri-
mers, lie within a region that is differentially methylated
(Figure 1C). The MSP technique was tested with
CXCL12 (island 2 and island 4) and ESR1 genes in DNA
from the tumour cell lines in order to confirm the
results from RT-PCR and data from the literature
(ESR1). The CXCL12 MSP results from breast tumour
cell lines were identical for the two islands (Figure 3A).
The MDA-MB-436, MDA-MB-435 and MDA-MB-231
breast tumour cell lines showed methylation of the two
islands, which is in agreement with the observed lack of
CXCL12 expression. In contrast, the HB4a, HB4aC3.6,
MCF-7 and PMC42 cell lines expressing CXCL12
showed no methylated bands (Figure 3A).
The ESR1 MSP results showed hypermethylation in
the MDA-MB-436, MDA-MB-435 and MDA-MB-231
breast tumour cell lines as well as in the HB4aC3.6 nor-
mal cell line. The HB4a normal cell line and the MCF-7
and PMC42 breast tumour cell lines did not show any
methylated bands (Figure 3A). These data corroborate
the literature [10,26] except in the case of cell lines
MDA-MB-436, PMC42 and HB4aC3.6, which have not
been previously described.
In this work, we did not evaluate normal breast tissue,
but Zhou et al. [27] used twenty normal samples and all
of them showed CXCL12 expression without methyla-
tion, which is in agreement with a possible tumoral
methylation specificity observed in our results.
MSP analysis in primary breast tumours
The MSP assay was subsequently used to analyse pri-
mary breast tumour samples. All samples showed the
band corresponding to the unmethylated state for
islands 2 and 4 (data not shown). Based on these results,
we can conclude that the samples have cellular hetero-
geneity due to the presence of normal tissue or infiltrat-
ing lymphocytes.
For the methylated condition, nine representative
tumour samples are shown (Figure 3B). Of all the sam-
ples tested (69), only four were methylated at both
islands, and three of these samples methylated at both
genes (Figure 3B). Moreover eighteen samples were
methylated in both, CXCL12 island 4 and ESR1 genes
(p = 0.0220). This finding indicates a strong correlation
between the promoter methylation of ESR1 and
CXCL12 island 4. In other words, methylation of the
ESR1 promoter could be involved in directing the
methylation of island 4 (see more details in
discussion).
We also wanted to confirm that the presence or
absence of island 2 or island 4 methylation observed in
MSP (Figure 3B) was not just a PCR artefact. Therefore,
we sequenced island 4 isolated from tumour samples 1,
3 and 8 (representative for banding pattern). Island 4
displayed 6% methylation in samples 1 and 3, and 89%
methylation in sample 8 (Figure 1D). These results are
in agreement with the PCR bands observed in the MSP.
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methylation status with patient clinicopathological data
The correlation between the CpG islands of CXCL12 and
ESR1 methylation and the clinicopathological parameters
of our samples are shown in Table 1. For island 2,
CXCL12 methylation was observed in ten of 69 (14.5%)
samples and was not significantly associated with any
clinicopathological data (Table 1a). For island 4, CXCL12
methylation was observed in 37 of 69 (54%) samples. The
clinicopathological parameters are shown in Table 1b
and hypermethylation in this region was significantly
associated with histological grade SBR (p = 0.0180),
metastasis (p = 0.0008) and death (p = 0.0019). These
results suggested that CpG island 4 might be important
as a factor for poor prognosis of disease. In order to test
this hypothesis we evaluated all of the clinicopathological
data for their prognostic value in a univariate analysis for
overall survival (OS) and metastasis-free survival (MFS)
using Kaplan-Meier analysis (p value for log rank test).
The overall survival (OS) was significantly worse for
many clinicopathological parameters, which are shown in
additional file 1. The graphical results for OS and MFS
are shown in Figure 4 for ESR1 and CXCL12.T h eO S
correlated with ESR1 (p = 0.0009) and CXCL12 island 4
(p = 0.0071) methylation (Figure 4A and 4B respectively).
The metastasis-free survival correlated with ESR1 and
CXCL12 island 4 (for both, p < 0.0001) (Figure 4C and
4D, respectively). The Kaplan-Meier analysis showed that
the overall survival and metastasis-free survival were sig-
nificantly shorter when silencing of CXCL12 island 4 and
ESR1 occurred by gene hypermethylation. The effects of
the covariables on OS and MFS were examined in the
Cox proportional hazard regression model. The results
for the univariate analysis are shown in Table 3. In the
multivariate analysis, all variables presenting p < 0.2 from
the univariate analysis were selected to build the multiple
model (Table 3). For overall survival, the presence of
metastasis (p = 0.0022) was considered a prognostic fac-
tor and ESR1 hypermethylation showed a statistical trend
(p=0.0555). Besides ERa, the hypermethylation of
CXCL12 island 4 and ESR1 genes (p = 0.0302, p=0.0089
and p = 0.0046, respectively) was considered an indepen-
dent prognostic factor for metastasis-free survival.
Patients with ERa protein present had the lowest risk of
metastasis development (HR 0.3343; 95% CI 0.1247-
0.8963). Otherwise, patients with methylation at both
CXCL12 island 4 and ESR1 genes had a risk of developing
metastasis, with CXCL12 island 4 having the highest risk
(HR 7.1355; 95% CI 1.6480-30.8958).
ESR1m e t h y l a t i o nw a so b s e r v e di n2 8o f6 9( 4 1 % )
tumour samples (Table 1c) and was not significantly
associated with age, HER2 or progesterone receptor
MDA-MB-436
MDA-MB-435
MDA-MB-231
MM NC
HB4a
HB4aC3.6
PMC42
MCF-7
300 bp
200 bp
200 bp
CXCL12
Island 2
CXCL12
Island 4
ESR1
A
300 bp
200 bp
200 bp
MM NC 123456 789
CXCL12
Island 2
CXCL12
Island 4
ESR1
Tumour samples B
Figure 3 CXCL12 and ESR1 methylation analyses of breast normal and tumour cell lines and MSP in primary breast tumours. (A) MSP
was performed using bisulphite treated DNA with primers that recognize methylated promoter only. The bands represent positive results for the
methylation in the islands 2 and 4 for CXCL12 and ESR1 genes. H2O was used as template in the negative control (NC). (B) Nine of sixty-nine
representative samples are included in the figure. Tumour samples were subjected to the MSP reaction, confirming the standardization done
with the cell lines for the methylated condition. The results for ESR1 showed promoter methylation in the samples 1 to 7 and 9. The tumour 1
presented both islands negative for methylation of CXCL12 gene; however ESR1 methylation was present even thought this sample is ERa
positive. The tumour 8 represented a sample with unmethylated ESR1. The lanes 1, 3 and 8 were representative sequenced samples after
bisulphite treatment (see Figure 1D).
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Page 8 of 13status, recurrence or histological type. On the other
hand, the stage (p = 0.0003), tumour size (p = 0.0029),
histological grade SBR (p = 0.0011), lymph node status
(p = 0.0288), oestrogen receptor status (p = 0.0054),
metastasis (p < 0.0001) and death (p = 0.0105) were
significantly associated with ESR1 gene methylation.
Statistical analyses demonstrated a correlation between
the intensity of ERa IHC staining and the frequency of
ESR1 promoter methylation. Nine out of eleven (82%)
ERa-negative cases were hypermethylated. Based on
the results from the immunohistochemical analyses, it
should be noted that of the samples scored as 0, 15
out of 25 (60%) were methylated; of the samples
scored as 1, 8 of the 22 (36%) were methylated; of the
samples scored as 2, 5 of the 16 (31%) were methy-
lated; and of the samples scored as 3, none of the six
samples were methylated (Figure 5). The number of
unmethylated and methylated samples for the scores
were submitted to a statistical Fisher’se x a c tt e s t ,a n d
statistical significance (p < 0.0001) was obtained (Fig-
ure 5). This result with ERa-negative status could be
due to many mechanisms, including epigenetic
mechanisms such as DNA methylation silencing.
These results suggest that in breast cancer patients,
silencing of the CXCL12 island 4 and ESR1 genes by
promoter hypermethylation can be used as a comple-
mentary marker for metastasis risk assessment.
Discussion
Breast cancer development and progression is influenced
by intrinsic properties of the tumour cells, as well as
macro-environmental factors. Extensive interplay exists
between the tumour cells and signalling molecules such
as chemokines. Muller et al. [3] showed that cancer
metastasis is a non-random process; organ selectivity by
the tumour cells is largely determined by factors that are
expressed in remote organs that eventually turn into pre-
ferred sites of metastases. Many reports have demon-
strated that chemokines are essential factors for the
invasion and survival of tumours [2]. However, many
other factors, such as the microenvironment of the breast
cancer cells and genetic and epigenetic alterations, might
be involved. Epigenetic events in tumours cells have the
ability to modulate gene expression and the role of epige-
netic alterations in cancer progression has been the focus
of increasing interest in recent years [24].
Table 3 Time to breast cancer progression in relation to clinicopathological characteristics: Cox proportional hazards
model
Analysis Overall survival Metastasis-free survival
HR 95% CI p value HR 95% CI p value
Univariate
Age 1.0074 0.9717 to 1.0444 0.6901 1.0134 0.9791 to 1.0490 0.4507
Stage 2.8065 1.1063 to 7.1200 0.0306 3.3893 1.4386 to 7.9850 0.0054
Grade 8.3473 1.1141 to 62.5437 0.0399 10.0599 1.3565 to 74.6075 0.0246
Tumour size 2.8301 1.0906 to 7.3445 0.0333 2.8825 1.1909 to 6.9770 0.0195
Lymph node 2.1072 0.9382 to 4.7326 0.0724 1.8045 0.8696 to 3.7445 0.1148
ERa 0.3322 0.1191 to 0.9265 0.0361 0.2413 0.0971 to 0.5992 0.0023
HER2 0.6813 0.3044 to 1.5247 0.3529 0.8075 0.4005 to 1.6280 0.5521
PR 0.727 0.3487 to 1.5159 0.3976 0.527 0.2614 to 1.0627 0.0749
Recurrence 2.0282 0.7885 to 5.2175 0.1444 1.7645 0.9107 to 3.4189 0.0940
Metastasis 7.824 2.7957 to 21.8962 < 0.0001
Death 2.4134 1.3737 to 4.2402 0.0022
Histological type 0.9002 0.2937 to 2.7597 0.8549 0.6848 0.2292 to 2.0455 0.4998
CXCL12 Island 4 4.1124 1.3539 to 12.4913 0.0130 11.5151 2.6886 to 49.3180 0.0010
CXCL12 Island 2 0.8083 0.2308 to 2.8313 0.7407 0.7528 0.2207 to 2.5676 0.6518
ESR1 3.2917 1.6312 to 6.6424 0.0009 3.1300 1.6632 to 5.8904 0.0004
Multivariate
Metastasis 5.2652 1.8200 to 15.2323 0.0022
ESR1 2.5752 0.9827 to 6.7484 0.0555 2.7569 1.0204 to 7.4486 0.0466
CXCL12 Island 4 * 7.1355 1.6480 to 30.8958 0.0089
ERa * 0.3343 0.1247 to 0.8963 0.0302
Tumour size * 1.9577 0.7137 to 5.3701 0.1942
Abbreviations: HR, hazard ration; CI, confidence interval; SBR, Scarff-Bloom-Richardson classification; ERa, estrogen receptor alpha; PR, progesterone receptor;
HER2, Human Epidermal growth factor Receptor-type 2. Statistical significance are in bold. * Variables that were not significant at Cox regression analysis.
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Page 9 of 13Figure 4 Kaplan-Meier curves for time to breast cancer progression according to CXCL12 methylation status. Kaplan-Meier estimates are
shown for overall survival using (A) ESR1 methylation, (B) CXCL12 island 4 methylation, and for metastasis-free survival using (C) ESR1
methylation, (D) CXCL12 island 4 methylation. Symbols on the graph lines represent censored data; p values are given for log rank tests.
Figure 5 Correlation of ESR1 methylation and protein score staining in the immunohistochemical analysis. The statistical data showed
the correlation between intensity of ERa staining by IHC and frequency of ESR1 promoter methylation. The dark bars denote methylated
samples and grey bars unmethylated samples. The samples with ERa expression (score 0 to 3, see material and methods) that showed
methylation were: scored 0 - 25 with 15 methylated (60%); score 1 - 22 with 8 methylated (36%); score 2 - 16 with 5 methylated (31%), score 3 -
6 samples without methylation. These results show the percentage of samples that were significant with p < 0.0001.
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Page 10 of 13In this study, we assessed the epigenetic regulation of
the CXCL12 and ESR1genes in breast cancer samples
from Brazilian women. The regulation of CXCL12
expression by promoter hypermethylation is common in
colon carcinoma [7] and breast cancer, suggesting that
tumour cells that silence CXCL12 are at a selective
advantage for metastasis [6,27]. In another recent study,
positive correlations between CXCL12 hypermethylation
and ERa-negative status were reported [27]. One of our
objectives was to verify in our samples the methylation
findings obtained in other female populations. We eval-
uated two CpG islands of the CXCL12 gene. The first
( i s l a n d2 )w a sh y p e r m e t h y l a t e di nt e no f6 9( 1 4 . 5 % )
tumour samples. This region had already been analysed
by another group that found DNA methylation in five of
15 (33.3%) American breast cancer samples [6]. In
another study [25] with patient samples from a Chinese
population, it was verified that 33 of 63 (52.4%) tumour
samples were hypermethylated in the same region.
These different results might be due to population or
environmental differences. The results for island 2
(Table 1a) showed that no statistical significance was
identified for any of the variables. We still do not know
if different populations might possess promoter regions
that are variable due to SNPs or other mechanisms that
can switch genes off.
We have also analysed the CXCL12 5’ upstream tran-
scription region in more detail and found a second CpG
island we refer to here as island 4, which is near a DNA
consensus site for transcriptional activation. Island 4 is
located 565 bps from the region studied by Garcia-Mor-
uja et al. [22], and we speculate that this region is
important for transcriptional regulation. However, Ante-
quera and Bird [28] argue that the importance of CpG
islands situated near the TSS is not always obvious, and
that new transcripts beginning in CpG islands distant
from the main promoter have been found. Island 4 is
located 19 bps away from a 5” oestrogen responsive ele-
ment (ERE) binding site. No data exist to prove that
these ERE consensus sequences could be functional.
However, Lin et al. [29] demonstrated discernable differ-
ences between functional and non-functional ERE sites
(1234 sites were found) and the CXCL12 gene was one
of the oestrogen-responsive genes identified in microar-
ray experiments. Other studies have demonstrated that
CXCL12 might be a target for oestrogen receptor bind-
ing [14,30]. We have concluded that the ERE proximal
to island 4 could be involved in the transcriptional regu-
lation of CXCL12. This interaction was modelled by Hall
and Korack [14], who suggested that oestrogen activates
CXCL12 expression. In this model, CXCL12 binds to
the cell surface receptor, CXCR4, in a potentially auto-
crine and/or paracrine (MAPK cascade) manner, result-
ing in the activation of cell proliferation.
The MSP results for island 4 (Table 1b) showed a sta-
tistical correlation with three variables related to metas-
tasis, reinforcing a probable role for island 4 in the
metastatic process. From these variables, we highlight
the correlation of island 4 hypermethylation with ESR1
silencing (Table 1c). In order to study this probable cor-
relation, Kaplan-Meier and Cox analyses were per-
formed. These analyses confirm that the silencing of
both CXCL12 island 4 and ESR1 genes by DNA hyper-
methylation and probably the absence of ERa, are prog-
nostic factors for metastasis-free survival (Table 3).
The results showed that ESR1 promoter methylation
occurred at a higher frequency in samples with methy-
lated CXCL12 island 4 than in samples with methylated
island 2 (Figure 3B). In addition, previous studies
[9,10,20,31] reported that the ESR1 gene possesses a
hypermethylated promoter region. This might explain
the correlation found in this study between the hyper-
methylation of CXCL12 island 4, but not island 2, and
the oestrogen receptor negativity. We speculate that
these effects are caused by the proximity of the CpG
island to an ERE. Curradi et al. [32] observed that the
presence of about eight methylated dinucleotides could
inhibit transcription because approximately 700 bps of
distance is required for chromatin modifications. There-
fore, it is possible that the methylation of island 4 could
attenuate or even inactivate ERE binding activity.
On the other hand, several studies have also shown
the inverse correlation. The absence of ERa could inac-
tivate target genes that possess an ERE site. It is known
that 60% of primary breast tumours are ERa-positive,
and two-thirds of the advanced tumours do not respond
to therapy with anti-estrogens such as tamoxifen
(Novaldex®). However, more than a third of patients do
not express ERa at the time of diagnosis, and a fraction
of tumours that are positive at the time of diagnosis
often lose ERa expression [9]. Breast tumour cells in
which ERa is absent cannot be regulated by oestrogen,
and endocrine therapy is not an option, resulting in a
poorer prognosis. Lapidus et al. [33] showed for the first
time that ESR1 is inactivated by CpG island DNA
methylation in cell lines and primary breast tumours.
The same group [31] also used MSP to show that breast
cancers expressing ERa had an unmethylated promoter
r e g i o n .M i r z ae ta l .[ 1 0 ]a n dZ h a oe ta l .[ 1 1 ]d e t e c t e d
66% and 60% ESR1 hypermethylation in Indian and Chi-
nese populations, respectively. Thus, the hypermethyla-
tion of ERa is commonly seen in several populations
and seems to be relevant to hormonal treatment
response. According to this, Leu et al. [34] proposed a
model suggesting that the progesterone receptor gene
(PGR) or another hypothetical target containing an ERE
consensus site inside the promoter region becomes
hypermethylated and silenced by repressor proteins
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Page 11 of 13when ERa is not expressed. In other words, ESR1 inacti-
vation and the consequent lack of ERa cause all target
genes to become susceptible to epigenetic silencing.
Apparently, ESR1 gene silencing by promoter hyper-
methylation and the consequent absence or decrease of
ERa expression are able to lead to CXCL12 gene silen-
cing by hypermethylation.
Consequently, the absence of CXCL12 signals the cells
to form metastasis in tumours with a high tumour grade
with negative ERa status, increasing the probability of
patient death. We do not yet know if island 4 hyper-
methylation could be involved in the chromatin altera-
tions associated with the blockage of ERa binding, or if
the absence of ERa due to epigenetic silencing can con-
tribute to the hypermethylation of CXCL12.
The results presented here show that epigenetic altera-
tions might play an important role in the downregula-
tion of CXCL12 mRNA in breast cancers in Brazilian
women. Our results, together with recent findings,
emphasise the importance of the CXCL12/CXCR4 sig-
nalling axis in the organ-specific patterns of metastasis.
Epigenetic events could regulate other genes involved in
the development of breast cancer and could also be
used to predict a better prognosis. The results presented
here could also be interpreted as a cause of the eventual
resistance seen in response to endocrine therapy.
Conclusions
Our results have shown, for the first time, a correlation
between hypermethylation of CXCL12 island 4 and
ESR1 in patients with histologically advanced cancer, the
presence of metastases and death. This correlation could
be an important factor in prognosis, cancer prevention
and treatment of these patients.
Additional file 1: Overall (OS) and metastasis-free survival (MFS)
probabilities calculated by Kaplan-Meier estimates (p value for log
rank test). Kaplan-Meier results for samples.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
23-S1.DOC]
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